Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Kenji Ohwaki"'
Publikováno v:
Journal of Diabetes Investigation, Vol 11, Iss 3, Pp 672-680 (2020)
Abstract Aims/Introduction Ultra‐rapid lispro (URLi) is a novel ultra‐rapid mealtime insulin. This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog®) in Japanese patients with typ
Externí odkaz:
https://doaj.org/article/8daafdf23073464d8fe17947034037f0
Autor:
John C Castle, Yoshikazu Hara, Christopher K Raymond, Philip Garrett-Engele, Kenji Ohwaki, Zhengyan Kan, Jun Kusunoki, Jason M Johnson
Publikováno v:
PLoS ONE, Vol 4, Iss 2, p e4369 (2009)
Acetyl-CoA carboxylases ACC1 and ACC2 catalyze the carboxylation of acetyl-CoA to malonyl-CoA, regulating fatty-acid synthesis and oxidation, and are potential targets for treatment of metabolic syndrome. Expression of ACC1 in rodent lipogenic tissue
Externí odkaz:
https://doaj.org/article/4970341b1eab4e9283fe1ceb74f92e09
Autor:
John C. Castle, Yoshikazu Hara, Christopher K. Raymond, Philip Garrett-Engele, Kenji Ohwaki, Zhengyan Kan, Jun Kusunoki, Jason M. Johnson
Publikováno v:
PLoS ONE, Vol 4, Iss 2 (2009)
Externí odkaz:
https://doaj.org/article/3f6bcfeb1f7346aa8092f1c3db817c64
Publikováno v:
Diabetes. 71
The aim was to investigate the safety, pharmacokinetics (PK) , and pharmacodynamics (PD) of once-weekly Basal Insulin Fc (BIF) , a novel long-acting IgG Fc-fusion protein being developed for the treatment of diabetes. This multiple-site, open-label,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::258a7a238d151003e0ec0423dfa78c1e
https://doi.org/10.2337/db22-802-p
https://doi.org/10.2337/db22-802-p
Autor:
Yasushi Takita, Hirotaka Nagashima, Risa Nasu, Kenji Ohwaki, Yukiko Nagai, Munehide Matsuhisa
Publikováno v:
Diabetes, Obesity and Metabolism. 22:1167-1175
Aim: To compare nasal glucagon (NG) with intramuscular glucagon (IMG) for the treatment of insulin‐induced hypoglycaemia in Japanese patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). Materials and methods: This phase 3, randomized, op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464ac0bfdeccd16c5e49f968147e34b4
https://doi.org/10.1111/dom.14019
https://doi.org/10.1111/dom.14019
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
Publikováno v:
Diabetes, obesitymetabolism. 24(2)
AIM To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Japanese participants with type 2 diabetes (T2D). METHODS This phase 1, double-blind, placebo-controlled, parallel-dose, multiple-ascendin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ab55e905182a8d93aee2556482eea1
https://pubmed.ncbi.nlm.nih.gov/34647404
https://pubmed.ncbi.nlm.nih.gov/34647404
Publikováno v:
Diabetes. 69
Dual GIP and GLP-1 receptor agonist, tirzepatide (TZP), showed clinically meaningful HbA1c reduction and dose-dependent weight loss in Japanese patients with type 2 diabetes in an 8-week, Phase 1, multiple ascending dose study. Decreased appetite was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2afcba119648b75e09b071c0b6b51f7f
https://doi.org/10.2337/db20-969-p
https://doi.org/10.2337/db20-969-p
Autor:
Kenji Ohwaki, Makoto Akimoto, Kenjiro Ono, Takuya Watanabe, Masanobu Yamada, Takahiro Inoue, Naoto Kato, Yoko Fujimoto, Makiko Kusama, Kiyoshi Kobayashi, Koji Uesugi, Katsuhiko Ichimaru, Masahisa Katsuno, Koichiro Yuji, Atsushi Hashizume, Harumasa Nakamura, Hiroshi Mizushima
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 48:141-147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d61bbe2242d1d7fd8076774b7ff44304
https://doi.org/10.3999/jscpt.48.141
https://doi.org/10.3999/jscpt.48.141